Literature DB >> 11697742

Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.

A Gaedigk1, W L Casley, R F Tyndale, E M Sellers, M Jurima-Romet, J S Leeder.   

Abstract

CYP2C9 is the major P450 2C enzyme in human liver and contributes to the metabolism of a number of clinically important substrate drugs. This polymorphically expressed enzyme has been studied in Caucasian, Asian, and to some extent in African American populations, but little is known about the genetic variation in Native American populations. We therefore determined the 2C9*2 (Arg144Cys) and 2C9*3 (Ile359Leu) allele frequencies in 153 Native Canadian Indian (CNI) and 151 Inuit subjects by PCR-RFLP techniques. We also present genotyping data for two reference populations, 325 Caucasian (white North American) and 102 Chinese subjects. Genotyping analysis did not reveal any 2C9*4 alleles in the CNI, Inuit, Caucasian, or Chinese individuals. The 2C9*2 allele appears to be absent in Chinese and Inuit populations, but was present in CNI and Caucasian subjects at frequencies of 0.03 and 0.08-0.15, respectively. The 2C9*3 allele was not detected in the Inuit group, but occured in the CNI group (f = 0.06) at a frequency comparable to that of other ethnic groups. This group of Inuit individuals are the first population in which no 2C9*2 or *3 alleles have been detected so far. Therefore, these alleles may be extremely rare or absent, and unless other novel polymorphisms exist in this Inuit group one would not anticipate any CYP2C9 poor metabolizer subjects among this population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697742

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  21 in total

1.  Allele and genotype frequency of CYP2C9 in Tamilnadu population.

Authors:  C Adithan; N Gerard; S Vasu; R Balakrishnan; C H Shashindran; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

2.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 3.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

4.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors:  K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

5.  Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity.

Authors:  Argyri Gialeraki; Christos Markatos; Elisabeth Grouzi; Efrosyni Merkouri; Anthi Travlou; Marianna Politou
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

6.  Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.

Authors:  Jung-woo Bae; Chang-ik Choi; Mi-jeong Kim; Da-hee Oh; Seul-ki Keum; Jung-in Park; Bo-hye Kim; Hye-kyoung Bang; Sung-gon Oh; Byung-sung Kang; Hyun-joo Park; Hae-deun Kim; Ji-hey Ha; Hee-jung Shin; Young-hoon Kim; Han-sung Na; Myeon-woo Chung; Choon-gon Jang; Seok-yong Lee
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

7.  Investigation of CYP2D6 Gene Polymorphisms in Turkish Population.

Authors:  Bayram Taskin; Ferda E Percin; Mehmet Ali Ergun
Journal:  Psychopharmacol Bull       Date:  2016-03-01

8.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

Review 9.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

10.  CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Authors:  Melih O Babaoglu; Umit Yasar; Mia Sandberg; Erik Eliasson; Marja-Liisa Dahl; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.